• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GINA 2020:初级保健的潜在影响、机遇和挑战。

GINA 2020: Potential Impacts, Opportunities, and Challenges for Primary Care.

机构信息

Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.

Department of Clinical Pharmacy & Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

出版信息

J Allergy Clin Immunol Pract. 2021 Apr;9(4):1516-1519. doi: 10.1016/j.jaip.2020.12.035. Epub 2020 Dec 26.

DOI:10.1016/j.jaip.2020.12.035
PMID:33373689
Abstract

In 2019, it was reported that changes to asthma management reported in the Global Initiative for Asthma (GINA) "…might be considered the most fundamental changes in asthma management in 30 years." These changes refer to the recommendation that the treatment of asthma in adolescents and adults would no longer include short-acting ß-agonist (SABA) only, but that people with asthma should receive either symptom-driven inhaled corticosteroids (ICS)-containing treatment (mild asthma) or daily ICS-containing treatment. The fundamental reason for this shift was driven by concerns about the risks and consequences associated with SABA-only treatment, the need to improve the day-to-day management of asthma symptoms to prevent exacerbations and emergent evidence. These recommendations have subsequently been reinforced and characterized in GINA 2020, and it is reasonable to say that they are significant, not only in terms of an asthma management framework but also as a management approach in practice. This opinion article specifically focuses on opportunities and challenges associated with the implementation of GINA 2020 in primary care practice that need to be recognized and addressed if the shift in asthma treatment paradigm is to be successfully implemented into day-to-day practice.

摘要

2019 年,据报道,全球哮喘倡议(GINA)中报告的哮喘管理变化“……可能被认为是 30 年来哮喘管理最根本的变化。”这些变化指的是建议不再将青少年和成人的哮喘治疗仅限于短效β-激动剂(SABA),而是应根据症状为患有哮喘的人提供含有吸入皮质激素(ICS)的治疗(轻度哮喘)或每天含有 ICS 的治疗。这种转变的根本原因是担心 SABA 单一治疗相关的风险和后果,需要改善哮喘症状的日常管理以预防恶化和出现新的证据。这些建议随后在 GINA 2020 中得到了强化和特征描述,可以合理地说,它们不仅在哮喘管理框架方面具有重要意义,而且在实践中的管理方法方面也具有重要意义。这篇观点文章特别关注在初级保健实践中实施 GINA 2020 时需要认识到的机会和挑战,如果要成功地将哮喘治疗模式的转变实施到日常实践中,这些机会和挑战就需要得到解决。

相似文献

1
GINA 2020: Potential Impacts, Opportunities, and Challenges for Primary Care.GINA 2020:初级保健的潜在影响、机遇和挑战。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1516-1519. doi: 10.1016/j.jaip.2020.12.035. Epub 2020 Dec 26.
2
Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction-Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA.《2019年全球哮喘防治创议(GINA)更新后轻度哮喘的实践模式专家意见:治疗范式的重大转变,从长期以来仅使用短效β2受体激动剂(SABA)的方法转向基于降低风险的策略,采用症状驱动(按需)低剂量吸入性糖皮质激素/长效β2受体激动剂(ICS/LABA)》
Curr Allergy Asthma Rep. 2022 Oct;22(10):123-134. doi: 10.1007/s11882-022-01038-x. Epub 2022 Jun 11.
3
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.全球哮喘倡议策略 2021:执行摘要和关键变化的理由。
J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S1-S18. doi: 10.1016/j.jaip.2021.10.001. Epub 2021 Oct 28.
4
It is time to change the way we manage mild asthma: an update in GINA 2019.是时候改变我们治疗轻度哮喘的方式了:GINA 2019 更新。
Respir Res. 2019 Aug 14;20(1):183. doi: 10.1186/s12931-019-1159-y.
5
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.《2021年全球哮喘防治创议策略:执行摘要及关键变化的基本原理》
Respirology. 2022 Jan;27(1):14-35. doi: 10.1111/resp.14174.
6
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update.2022 年全球哮喘倡议(GINA)更新:初级保健的主要建议。
NPJ Prim Care Respir Med. 2023 Feb 8;33(1):7. doi: 10.1038/s41533-023-00330-1.
7
[Novelties in the Treatment of Asthma].[哮喘治疗的新进展]
Praxis (Bern 1994). 2021;110(16):967-974. doi: 10.1024/1661-8157/a003760. Epub 2021 Oct 27.
8
[From a trail to an official path: new recommendations for the treatment of mild asthma].[从试验到正式指南:轻度哮喘治疗的新建议]
Dtsch Med Wochenschr. 2020 Jun;145(11):767-771. doi: 10.1055/a-1003-7142. Epub 2020 Jun 3.
9
As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?按需使用 ICS-LABA 治疗轻度哮喘:证据说了什么?
Drugs. 2019 Nov;79(16):1729-1737. doi: 10.1007/s40265-019-01202-0.
10
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.全球哮喘倡议 2021 策略:执行摘要和关键变更的理由。
Am J Respir Crit Care Med. 2022 Jan 1;205(1):17-35. doi: 10.1164/rccm.202109-2205PP.

引用本文的文献

1
Application of fractional exhaled nitric oxide and nasal nitric oxide in the evaluation of asthma control.呼出气一氧化氮分数和鼻一氧化氮在哮喘控制评估中的应用。
Front Pediatr. 2025 Jul 7;13:1567548. doi: 10.3389/fped.2025.1567548. eCollection 2025.
2
Perceptions and practices of community pharmacists towards the use of short-acting beta-2 agonists inhalers in Malaysia: A cross-sectional survey.马来西亚社区药剂师对使用短效β-2激动剂吸入器的认知与实践:一项横断面调查。
PLoS One. 2025 Jun 11;20(6):e0324982. doi: 10.1371/journal.pone.0324982. eCollection 2025.
3
Involvement of the Constitutive Photomorphogenesis 9 Signalosome Subunit 5 With Programmed Cell Death Protein 1 Ligand in Asthma.
组成型光形态建成9信号体亚基5与程序性细胞死亡蛋白1配体在哮喘中的作用
Allergy Asthma Immunol Res. 2024 Sep;16(5):505-519. doi: 10.4168/aair.2024.16.5.505.
4
Over-the-counter use of short-acting beta-2 agonists: a systematic review.短效β-2激动剂的非处方使用:一项系统评价
J Pharm Policy Pract. 2023 Oct 9;16(1):119. doi: 10.1186/s40545-023-00627-z.
5
Impact of the Junction Adhesion Molecule-A on Asthma.Junction Adhesion Molecule-A 对哮喘的影响。
Yonsei Med J. 2023 Jun;64(6):375-383. doi: 10.3349/ymj.2022.0503.
6
Developing a Smartphone Application That Promotes Responsible Short-Acting Beta2-Agonist Use in People with Asthma: A Participatory Design.开发一款促进哮喘患者负责任使用短效β2-激动剂的智能手机应用程序:一项参与式设计。
Int J Environ Res Public Health. 2022 Jul 12;19(14):8496. doi: 10.3390/ijerph19148496.
7
Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity.降低哮喘严重程度两端对短效β2受体激动剂(SABA)和口服糖皮质激素(OCS)的耐受性。
J Pers Med. 2022 Mar 21;12(3):504. doi: 10.3390/jpm12030504.
8
Serum Amyloid A1: A Biomarker for Neutrophilic Airway Inflammation in Adult Asthmatic Patients.血清淀粉样蛋白A1:成人哮喘患者中性粒细胞气道炎症的生物标志物
Allergy Asthma Immunol Res. 2022 Jan;14(1):40-58. doi: 10.4168/aair.2022.14.1.40.